Liver Model

In October, 2009, HemoShear announced the formation of a new division called HepaShear. Shortly thereafter, we announced that Edward LeCluyse, Ph.D., had joined HepaShear to lead development of an advanced human surrogate model of the liver to study liver diseases and accelerate discovery of innovative new drug therapies.

Utilizing HemoShear’s proprietary technology, which applies human blood flow patterns to recreate the biology of human tissue, HepaShear will incorporate blood flow patterns of the liver with human primary cell cultures that mimic the structure of the liver. The HepaShear human surrogate model will vastly improve scientists’ abilities to study liver functions and diseases.

HepaShear will work in close research and development collaborations with pharmaceutical partners to identify new drug targets and discover compounds that have a greater likelihood of successful treatment of liver diseases in humans. The graphic below depicts several areas in which the HepaShear human surrogate model will be deployed.